Aldebaran Therapeutics
Waltham, US · Founded 2022 · Delaware corporation · 4 employees on LinkedIn · 1 known investors
Founders & leadership
CP
Chris PachecoNamed on SEC filing
CL
Carlos LoyaNamed on SEC filing
Board
LM
Investors · 1
Reported raises · per SEC filings
Form D private placements$800K disclosed across 1 round · 2022
▶$800KraisedMar 2022 · 20 investors · BiotechnologyRule 506(b)
▶$800KraisedMar 2022 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lauren MifflinDirector
- Chris PachecoDirector
- Carlos LoyaExecutive Officer, Director
- Offering amount
- $1.2M
- Amount sold
- $800K
- Proceeds to insiders
- $150K
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Aldebaran Therapeutics's investors?
- Aldebaran Therapeutics's investors include Frazier Life Sciences.
- How much funding has Aldebaran Therapeutics raised?
- Aldebaran Therapeutics has disclosed $800K raised across 1 round.
- Where is Aldebaran Therapeutics headquartered?
- Aldebaran Therapeutics is headquartered in Waltham, US.